Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI-generated claims partially align with the label. It correctly notes that Arnuity Ellipta is an inhalation powder and exists in multiple strengths and packaging. However, it includes an incorrect assertion regarding the absence of a 50 mcg strength, omits critical safety information (contraindications, boxed warnings, use in pregnancy, pediatric safety), and mischaracterizes available pack sizes (no 60-dose pack described). Overall, there are notable safety omissions and at least one incorrect dosage claim.
Category Scores
Accurate Statements
Arnuity Ellipta is an inhalation powder containing fluticasone furoate.
11
Arnuity Ellipta strengths include 50 mcg, 100 mcg, and 200 mcg per blister.
3
Unsupported Statements
Inhaler pack sizes: 60-dose inhaler pack.
Label describes 30-dose packs and 14-dose institutional packs; no 60-dose pack is described.
Dose strength examples: 50 mcg vs 100 mcg.
Label supports both 50 mcg and 100 mcg strengths; the claim as presented is not unsupported, but the accompanying assertion in the evaluation that 50 mcg is not listed is incorrect.
50 mcg is not a listed strength.
Label lists 50 mcg as a strength; this assertion is contradicted by label content.
Contradictions
Low
AI Statement
50 mcg is not a listed strength.
Label Reference
3
Important Omissions
Indication(s) for Arnuity Ellipta
Importance:
High
Contraindications
Importance:
High
Boxed warnings
Importance:
High
Pregnancy risk summary / Use in specific populations (pregnancy, lactation, pediatric, geriatrics)
Importance:
Moderate
Pediatric safety information (growth effects, age range for use, dosing considerations)
Importance:
Moderate
Dosing safety details (initiation, max daily dose, spacing, renal/hepatic considerations)
Importance:
Moderate
Guidance on minimizing oropharyngeal candidiasis (e.g., mouth rinsing after inhaled corticosteroid use)
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Notable safety content is omitted, but no explicit adverse risk statements are provided in the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Missing safety details and an incorrect dosage claim regarding strength availability.
Suggested Improvement
Include complete safety information (indications, contraindications, boxed warnings, use in specific populations, adverse reactions, monitoring), provide accurate dosage details (confirmed strengths 50, 100, 200 mcg per dose), clarify permissible pack sizes (30-dose inhalers and 14-dose institutional packs), and supply clear administration and storage guidelines.